Skip to content
Biotechnology, Medical Health Aged Care

Blood test to detect dementia: expert available for comment

Neuroscience Research Australia < 1 mins read
Prof Matthew Kiernan AM is a distinguished clinical academic and scientist renowned for his expertise in neurodegenerative diseases, particularly motor neuron disease (MND) and frontotemporal dementia (FTD)

Professor Matthew Kiernan AM CEO at Neuroscience Research Australia is available to provide expert comment on the development of an early blood test to predict dementia, as reported by the Guardian today based on research published in nature aging

Professor Kiernan AM is an expert in neurodegenerative diseases, particularly motor neuron disease (MND) and frontotemporal dementia (FTD). He is a clinician scientist based at NeuRA. 

 


Contact details:

Contact Michelle Smith OR Beatrix Kates

Senior Communications & PR Officer

0452 140 477

michelle.smith@neura.edu.au

b.kates@neura.edu.au

 

Media

More from this category

  • Medical Health Aged Care
  • 16/07/2024
  • 06:00
Monash University

Why early life antibiotic use can increase risk of asthma: a potential prevention for asthma later in life?

Early exposure to antibiotics can trigger long term susceptibility to asthma, according to new research from Monash University. Importantly the research team isolated a molecule produced by gut bacteria that in the future could potentially be trialed as a simple treatment, in the form of a dietary supplement, for children at risk of asthma to prevent them developing the disease. Asthma affects over 260 million people globally and causes around 455,000 deaths annually. In Australia, 2.7 million people live with asthma and for 45% of these people, their asthma is poorly controlled. The research led by Professor Ben Marsland and…

  • Biotechnology
  • 15/07/2024
  • 20:11
Moolec Science SA

Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025

LUXEMBOURG / ACCESSWIRE / July 15, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec's patented science-based GLA Safflower Oil product, GLASO™ (the "Agreement"). This initial offtake agreement has a term of three years and establishes commercial conditions for the delivery of GLASO™ in US territory with an initial estimated volume of 50 tons for 2025.Moolec Science Logo GLASO™ is a nutritional omega 6 oil obtained from bioengineered safflower seeds.…

  • Business Company News, Medical Health Aged Care
  • 15/07/2024
  • 11:55
Jane Morgan Management

Heramed Limited (ASX:HMD) and UTS Sign Five-Year Strategic Partnership Focused on Care and Wellbeing of Women and Babies

Melbourne, Australia – 15 July 2024 | Heramed Ltd (ASX: HMD) ("Heramed" or the "Company"), a pioneering medical data and technology company transforming maternity care, is pleased to announce the signing of a five-year Strategic Partnership Agreement (SPA) with the University of Technology Sydney (UTS). This partnership is led by UTS's INSIGHT Health Research Institute, a renowned centre for innovative health solutions. Key Highlights: Strategic Partnership: Heramed and UTS have entered a five-year strategic partnership through the leadership of INSIGHT Health Research Institute, focusing on improving the care and wellbeing of women and babies. Collaboration Scope: UTS, a leading Australian…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.